In the present study, we consistently found that patients with CKD stage 5, compared with stages 3b/4, had low circulating Trp levels coupled with high levels of KP pathway metabolites, indicating enhanced IDO activity. The gene discussed is IDO1; the disease is chronic kidney disease.